Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.

Slamon DJ, Press MF.

J Natl Cancer Inst. 2009 May 6;101(9):615-8. doi: 10.1093/jnci/djp092. Epub 2009 Apr 28. No abstract available.

PMID:
19401550
[PubMed - indexed for MEDLINE]
Free Article
2.

Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?

Di Leo A, Isola J.

Clin Breast Cancer. 2003 Aug;4(3):179-86. Review.

PMID:
14499010
[PubMed - indexed for MEDLINE]
3.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

PMID:
19365520
[PubMed - indexed for MEDLINE]
Free Article
4.

HER-2 and topoisomerase II as predictors of response to chemotherapy.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B.

J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716. Review.

PMID:
18258981
[PubMed - indexed for MEDLINE]
5.

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.

Cancer Treat Rev. 2009 Dec;35(8):662-7. doi: 10.1016/j.ctrv.2009.08.006. Epub 2009 Sep 15. Review.

PMID:
19758759
[PubMed - indexed for MEDLINE]
6.

Anthracyclines in early-stage breast cancer: is it the end of an era?

Robson D, Verma S.

Oncologist. 2009 Oct;14(10):950-8. doi: 10.1634/theoncologist.2008-0070. Epub 2009 Jun 26. Review. Erratum in: Oncologist. 2009 Dec;14(12):1252.

PMID:
19561291
[PubMed - indexed for MEDLINE]
Free Article
7.

[Topo II alpha in breast cancer: an update].

Wei J, Liu FF, Fu L.

Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):132-5. Review. Chinese. No abstract available.

PMID:
18681328
[PubMed - indexed for MEDLINE]
8.

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D.

Eur J Cancer. 2008 Dec;44(18):2791-8. doi: 10.1016/j.ejca.2008.09.014. Epub 2008 Nov 5. Review.

PMID:
18993056
[PubMed - indexed for MEDLINE]
9.

Current status of prognostic profiling in breast cancer.

Pusztai L.

Oncologist. 2008 Apr;13(4):350-60. doi: 10.1634/theoncologist.2007-0216. Review.

PMID:
18448548
[PubMed - indexed for MEDLINE]
Free Article
10.

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V.

Cancer Treat Rev. 2007 Feb;33(1):64-77. Epub 2006 Nov 17. Review.

PMID:
17113234
[PubMed - indexed for MEDLINE]
11.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

PMID:
21435434
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.

Gennari A, Pronzato P.

Clin Breast Cancer. 2008 Dec;8 Suppl 4:S179-83. doi: 10.3816/CBC.2008.s.015. Review.

PMID:
19158039
[PubMed - indexed for MEDLINE]
13.

Prognostic and predictive factors.

Biganzoli L.

Cancer Treat Res. 2009;151:13-30. doi: 10.1007/978-0-387-75115-3_2. Review. No abstract available.

PMID:
19593503
[PubMed - indexed for MEDLINE]
14.

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.

Järvinen TA, Liu ET.

Cytopathology. 2003 Dec;14(6):309-13. Review.

PMID:
14632727
[PubMed - indexed for MEDLINE]
15.

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB.

Lancet Oncol. 2009 Mar;10(3):267-77. doi: 10.1016/S1470-2045(09)70063-4. Review.

PMID:
19261255
[PubMed - indexed for MEDLINE]
16.

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.

Munro AF, Cameron DA, Bartlett JM.

Oncogene. 2010 Sep 23;29(38):5231-40. doi: 10.1038/onc.2010.286. Epub 2010 Aug 2. Review.

PMID:
20676126
[PubMed - indexed for MEDLINE]
17.

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Romero A, Caldés T, Díaz-Rubio E, Martín M.

Clin Transl Oncol. 2012 Mar;14(3):163-8. doi: 10.1007/s12094-012-0779-1. Review.

PMID:
22374418
[PubMed - indexed for MEDLINE]
18.

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ.

Biochim Biophys Acta. 2013 Aug;1836(1):146-57. doi: 10.1016/j.bbcan.2013.04.004. Epub 2013 Apr 26. Review.

PMID:
23628726
[PubMed - indexed for MEDLINE]
19.

HER-2 and choice of adjuvant chemotherapy in breast cancer.

Paik S, Park C.

Semin Oncol. 2001 Aug;28(4):332-5. Review.

PMID:
11498827
[PubMed - indexed for MEDLINE]
20.

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.

Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T.

Int J Clin Oncol. 2009 Apr;14(2):112-9. doi: 10.1007/s10147-008-0813-z. Epub 2009 Apr 24. Review.

PMID:
19390941
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk